Literature DB >> 32329959

Chemically Programmable and Switchable CAR-T Therapy.

Junpeng Qi1, Kohei Tsuji2,3, David Hymel2, Terrence R Burke2, Michael Hudecek4, Christoph Rader1, Haiyong Peng1.   

Abstract

Although macromolecules on cell surfaces are predominantly targeted and drugged with antibodies, they harbor pockets that are only accessible to small molecules and constitutes a rich subset of binding sites with immense potential diagnostic and therapeutic utility. Compared to antibodies, however, small molecules are disadvantaged by a less confined biodistribution, shorter circulatory half-life, and inability to communicate with the immune system. Presented herein is a method that endows small molecules with the ability to recruit and activate chimeric antigen receptor T cells (CAR-Ts). It is based on a CAR-T platform that uses a chemically programmed antibody fragment (cp-Fab) as on/off switch. In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding proteins on the cell surface mediated potent and specific eradication of folate-receptor-expressing cancer cells in vitro and in vivo.
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CAR-Ts; antibodies; antitumor agents; cell-surface receptors; immunotherapy

Mesh:

Substances:

Year:  2020        PMID: 32329959      PMCID: PMC7429910          DOI: 10.1002/anie.202005432

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  43 in total

Review 1.  Folate-targeted therapies for cancer.

Authors:  Wei Xia; Philip S Low
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

Review 2.  Chemical probes and drug leads from advances in synthetic planning and methodology.

Authors:  Christopher J Gerry; Stuart L Schreiber
Journal:  Nat Rev Drug Discov       Date:  2018-04-13       Impact factor: 84.694

3.  Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis.

Authors:  B List; C F Barbas; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Target 2035: probing the human proteome.

Authors:  Adrian J Carter; Oliver Kraemer; Matthias Zwick; Anke Mueller-Fahrnow; Cheryl H Arrowsmith; Aled M Edwards
Journal:  Drug Discov Today       Date:  2019-07-03       Impact factor: 7.851

5.  A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Authors:  Xiuli Wang; Wen-Chung Chang; ChingLam W Wong; David Colcher; Mark Sherman; Julie R Ostberg; Stephen J Forman; Stanley R Riddell; Michael C Jensen
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 6.  CAR T cell immunotherapy for human cancer.

Authors:  Carl H June; Roddy S O'Connor; Omkar U Kawalekar; Saba Ghassemi; Michael C Milone
Journal:  Science       Date:  2018-03-23       Impact factor: 47.728

7.  In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

Authors:  De-Gang Song; Qunrui Ye; Carmine Carpenito; Mathilde Poussin; Li-Ping Wang; Chunyan Ji; Mariangela Figini; Carl H June; George Coukos; Daniel J Powell
Journal:  Cancer Res       Date:  2011-05-05       Impact factor: 12.701

8.  Chemically Programmed Bispecific Antibodies in Diabody Format.

Authors:  Even Walseng; Christopher G Nelson; Junpeng Qi; Alex R Nanna; William R Roush; Rajib K Goswami; Subhash C Sinha; Terrence R Burke; Christoph Rader
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

9.  A mass spectrometric-derived cell surface protein atlas.

Authors:  Damaris Bausch-Fluck; Andreas Hofmann; Thomas Bock; Andreas P Frei; Ferdinando Cerciello; Andrea Jacobs; Hansjoerg Moest; Ulrich Omasits; Rebekah L Gundry; Charles Yoon; Ralph Schiess; Alexander Schmidt; Paulina Mirkowska; Anetta Härtlová; Jennifer E Van Eyk; Jean-Pierre Bourquin; Ruedi Aebersold; Kenneth R Boheler; Peter Zandstra; Bernd Wollscheid
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

10.  Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.

Authors:  Diana Darowski; Sebastian Kobold; Christian Jost; Christian Klein
Journal:  MAbs       Date:  2019-04-17       Impact factor: 5.857

View more
  6 in total

1.  ROR1-targeting switchable CAR-T cells for cancer therapy.

Authors:  Haiyong Peng; Thomas Nerreter; Katrin Mestermann; Jakob Wachter; Jing Chang; Michael Hudecek; Christoph Rader
Journal:  Oncogene       Date:  2022-07-20       Impact factor: 8.756

2.  Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells.

Authors:  Yi-Chiu Kuo; Cheng-Fu Kuo; Kurt Jenkins; Alfur Fu-Hsin Hung; Wen-Chung Chang; Miso Park; Brenda Aguilar; Renate Starr; Jonathan Hibbard; Christine Brown; John C Williams
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

Review 3.  Application and Design of Switches Used in CAR.

Authors:  Paweł Głowacki; Piotr Rieske
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

Review 4.  Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer.

Authors:  Caili Xu; Dianwen Ju; Xuyao Zhang
Journal:  Antib Ther       Date:  2022-02-23

Review 5.  Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.

Authors:  Prameela Kandra; Rajender Nandigama; Bastian Eul; Magdalena Huber; Sebastian Kobold; Werner Seeger; Friedrich Grimminger; Rajkumar Savai
Journal:  Front Immunol       Date:  2022-06-02       Impact factor: 8.786

6.  Light-Controllable Binary Switch Activation of CAR T Cells.

Authors:  Aya Kobayashi; Alberto Nobili; Steven C Neier; Amissi Sadiki; Robert Distel; Zhaohui Sunny Zhou; Carl D Novina
Journal:  ChemMedChem       Date:  2022-02-21       Impact factor: 3.540

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.